Trial Profile
Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Combi-Neo
- 08 Feb 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 08 Feb 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
- 24 Oct 2023 Pooled analysis result of NCT02231775 and NCT02519322 trial assessing relapse free survival at 3 years by pathological response to neoadjuvant systemic treatment in patients with surgically resectable, high-risk melanoma (n=97) presented at the 48th European Society for Medical Oncology Congress.